Review

mouse breast cancer cell line (ATCC)

ATCC is a verified supplier

ATCC manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

ATCC mouse breast cancer cell line

Paclitaxel and its combination with nintedanib increased median survival in the advanced metastatic <t>breast</t> <t>cancer</t> LM2–4 model. a ) Kaplan-Meier survival curves and median survival values. Paclitaxel (PTX) significantly increased median survival compared to the control group ( p = 0.033; Log-rank (Mantel Cox) Test, n = 8–10). Combination therapy increased median survival (81 days vs 60.5 days, control group) but it did not reach significance. Treatment started around 40 days after <t>cell</t> implantation. b) Effect of sunitinib alone and when combined with PTX in the advanced metastatic LM2–4 breast cancer model. Kaplan-Meier survival curves and median survival values. Modified from Guerin et al., 2013 . PTX alone increased survival whereas sunitinib alone did not, and adding sunitinib to PTX did not result in increased efficacy

Mouse Breast Cancer Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 93/100, based on 62 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+models/Breast+Cancer+Mouse+Model+Cell+Line+Panel/pmc06330500-57-4-2
Average 93 stars, based on 62 article reviews

mouse breast cancer cell line - by Bioz Stars, 2026-09

93/100 stars

Images

1) Product Images from "Therapeutic impact of Nintedanib with paclitaxel and/or a PD-L1 antibody in preclinical models of orthotopic primary or metastatic triple negative breast cancer"

Article Title: Therapeutic impact of Nintedanib with paclitaxel and/or a PD-L1 antibody in preclinical models of orthotopic primary or metastatic triple negative breast cancer

Journal: Journal of Experimental & Clinical Cancer Research : CR

doi: 10.1186/s13046-018-0999-5

Paclitaxel and its combination with nintedanib increased median survival in the advanced metastatic breast cancer LM2–4 model. a ) Kaplan-Meier survival curves and median survival values. Paclitaxel (PTX) significantly increased median survival compared to the control group ( p = 0.033; Log-rank (Mantel Cox) Test, n = 8–10). Combination therapy increased median survival (81 days vs 60.5 days, control group) but it did not reach significance. Treatment started around 40 days after cell implantation. b) Effect of sunitinib alone and when combined with PTX in the advanced metastatic LM2–4 breast cancer model. Kaplan-Meier survival curves and median survival values. Modified from Guerin et al., 2013 . PTX alone increased survival whereas sunitinib alone did not, and adding sunitinib to PTX did not result in increased efficacy

Figure Legend Snippet: Paclitaxel and its combination with nintedanib increased median survival in the advanced metastatic breast cancer LM2–4 model. a ) Kaplan-Meier survival curves and median survival values. Paclitaxel (PTX) significantly increased median survival compared to the control group ( p = 0.033; Log-rank (Mantel Cox) Test, n = 8–10). Combination therapy increased median survival (81 days vs 60.5 days, control group) but it did not reach significance. Treatment started around 40 days after cell implantation. b) Effect of sunitinib alone and when combined with PTX in the advanced metastatic LM2–4 breast cancer model. Kaplan-Meier survival curves and median survival values. Modified from Guerin et al., 2013 . PTX alone increased survival whereas sunitinib alone did not, and adding sunitinib to PTX did not result in increased efficacy

Techniques Used: Control, Modification

Improvement of immunotherapy efficacy when treating primary tumors with nintedanib combination therapy . a ) Tumor growth in the primary EMT-6 breast cancer model. Treatment was started when average tumor volume was 120mm 3 , around 7 days after cell implantation. Statistical analysis on day 27. ANOVA followed by Tukey’s Multiple Comparison Test * p < 0.05, ** p < 0.01. Data are presented as means ± SD, n = 6. Region of flat line in the curves means that tumor in remaining mice had regressed, and in the case of mice treated with PD-L1 antibody, tumors grew back. Mice were treated with nintedanib and/or paclitaxel (PTX) for 70 days, and then treatment stopped. b) Tumor growth in the primary EMT-6/CDDP model. Treatment was started when average tumor volume was 120mm 3 , 7 days after cell implantation. Statistical analysis on day 27. Kruskal-Wallis test followed by Dunn’s Multiple Comparison Test, ** p < 0.01. Data are presented as means ± SD, n = 9–12. c-f) Effect of nintedanib, paclitaxel, anti-PD-L1 and the drug combinations on c) Vascularity; d) Proliferation; e) CD8+ tumor infiltrating cells; and f) Level of Necrosis. Histology and immunohistochemistry analyses were performed on tumor samples obtained from mice implanted with EMT-6/CDDP cells. Treatment was started when average tumor volume was 120mm 3 and all mice were sacrificed after 10 days of treatment. The Mann-Whitney test was used for statistical analyses. Data are presented as means ± SD, n = 6–7

Figure Legend Snippet: Improvement of immunotherapy efficacy when treating primary tumors with nintedanib combination therapy . a ) Tumor growth in the primary EMT-6 breast cancer model. Treatment was started when average tumor volume was 120mm 3 , around 7 days after cell implantation. Statistical analysis on day 27. ANOVA followed by Tukey’s Multiple Comparison Test * p < 0.05, ** p < 0.01. Data are presented as means ± SD, n = 6. Region of flat line in the curves means that tumor in remaining mice had regressed, and in the case of mice treated with PD-L1 antibody, tumors grew back. Mice were treated with nintedanib and/or paclitaxel (PTX) for 70 days, and then treatment stopped. b) Tumor growth in the primary EMT-6/CDDP model. Treatment was started when average tumor volume was 120mm 3 , 7 days after cell implantation. Statistical analysis on day 27. Kruskal-Wallis test followed by Dunn’s Multiple Comparison Test, ** p < 0.01. Data are presented as means ± SD, n = 9–12. c-f) Effect of nintedanib, paclitaxel, anti-PD-L1 and the drug combinations on c) Vascularity; d) Proliferation; e) CD8+ tumor infiltrating cells; and f) Level of Necrosis. Histology and immunohistochemistry analyses were performed on tumor samples obtained from mice implanted with EMT-6/CDDP cells. Treatment was started when average tumor volume was 120mm 3 and all mice were sacrificed after 10 days of treatment. The Mann-Whitney test was used for statistical analyses. Data are presented as means ± SD, n = 6–7

Techniques Used: Comparison, Immunohistochemistry, MANN-WHITNEY

other:

Article Title: Preclinical Tumor Growth Delay Is More Reliable from Imaging-Based Rather than Manual Caliper Volume Measurements
Article Snippet: Cell lines: 4T1, a mouse-derived breast cancer cell line, which mimics human stage IV breast cancer in BALB/c mice, was purchased from ATCC (#CRL-2539).

Article Title: Antitumor agent and antitumor effect potentiator
Article Snippet: EMT6, a mouse breast cancer cell line, was obtained from American Type Culture Collection (ATCC).

Article Title: Semaphorin 3F inhibits breast cancer metastasis by regulating the Akt-mTOR and TGFβ signaling pathways via neuropilin-2
Article Snippet: The human and mouse breast cancer cells were supplied by the American Type Culture Collection.

Article Title: Antitumor agent and antitumor effect potentiator
Article Snippet: EMT6, a mouse breast cancer cell line, was obtained from ATCC.

Injection:

Article Title: Tumor vascular disruption and cGAS–STING activation by gambogic amide-loaded nanomicelles for multiple synergistic treatment of triple-negative breast cancer
Article Snippet: Female BALB/c mice (6–8 weeks old) were procured from Jiangsu Jicui Laboratory Animal Co. All experiments adhered to protocols sanctioned by the Experimental Animal Center of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology. .. Mouse breast cancer cells (4T1; the ATCC) were injected subcutaneously (2 × 106 cells) into mice to create a subcutaneous tumor model. Tumor size calculation was conducted as V = length × width × width/2 (mm3). ..